
Anavex Life Sciences Corp
AVXLNASDAQ NMS - GLOBAL MARKETKey Statistics
Open
$2.95
Day High
$3.04
Day Low
$2.81
Prev. Close
$2.94
VolumeShares traded today.
1.30M
Avg. VolumeAverage daily volume.
—
Market CapTotal value of all shares = price × shares outstanding.
$280.80M
P/E (TTM)Price-to-Earnings: share price ÷ earnings per share over the last 12 months. Lower can mean cheaper; very high can mean growth expectations.
-6.52
Forward P/EP/E based on forecast next-year earnings.
—
P/B RatioPrice-to-Book: share price ÷ book value per share.
—
52W HighHighest price over the past 52 weeks.
$13.99
52W LowLowest price over the past 52 weeks.
$2.61
50D MAAverage closing price over the last 50 trading days.
$3.20
200D MAAverage closing price over the last 200 trading days.
$5.50
Dividend YieldAnnual dividend ÷ share price, as a %.
—
BetaVolatility vs the market. >1 = more volatile than the S&P 500.
—
Performance
1W
+11.8%1M
-7.1%6M
-12.4%YTD
-17.7%1Y
-59.8%About
ANAVEX 1-41, or ANAVEX1-41, is an experimental drug which is or was under development for the treatment of depressive disorders, neurodegenerative disorders, and stroke. It is a sigma σ1 receptor agonist, non-selective muscarinic acetylcholine receptor modulator, and sodium and chloride channel modulator. The drug is a positional isomer of blarcamesine and has similar actions. It was under development by Anavex Life Sciences. ANAVEX 1-41 reached the preclinical research stage of development prior to no recent development being reported as of 2022. It was intended as a backup compound for blarcamesine. The drug was first described in the scientific literature by 2007.
www.anavex.comCompany Facts
Similar stocks
Health CareSentiment
Latest News
Social Noise
Price Alerts
Loading…
Trade AVXL
Brokers available in your region (US)
Affiliate links — we may earn a commission. CFDs are risky.